Roche heads to regulators with new autoimmune win for Gazyva
Continuing the reinvention of its cancer drug Gazyva as a treatment for immune-mediated diseases of the kidney—which resulted…
Roche Gazyva/Gazyvaro Gets FDA Priority Review
Roche (OTCQX:RHHBY) reported that the US FDA granted Priority Review to its supplemental Biologics License…
RHHBY’s Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER | News
Swiss pharma giant Roche Holding AG’s RHHBY first-quarter 2026 results were affected by currency headwinds. Sales totaled $18.8…
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Roche (RHHBY) announced on 3 November 2025 that the phase III ALLEGORY study…